ZYHCG 10000 iu (ex.Ovidac)
- Brand: Cadila, India
- Product Code: ZYHCG 10000 iu (ex.Ovidac)
- Availability: In Stock
-
$56.00
Manufacturer: Cadila, India
Pharmaceutical name: Human Chorionic Gonadotropin
Pack: 1 set (vial 10000 iu + solution)
ZYHCG is a hormone that the female placenta produces naturally during a typical pregnancy. The effects of this medication closely resemble those of luteinizing hormone (LH), as LH is known to trigger ovulation. When used alongside other medications, ZYHCG is particularly effective in assisting female patients in achieving pregnancy. Additionally, it can assist male patients facing fertility challenges, often resulting in increased testosterone production.
ZYHCG 10000 iu is a commonly prescribed medication for female patients as part of a protocol aimed at inducing: Ovulation induction in cases of subfertility typically caused by impaired follicle maturation or anovulation. - Luteal phase support. Follicle preparation for aspiration in controlled ovarian hyperstimulation programs (usually applied in medically assisted reproductive techniques).
ZYHCG is also frequently prescribed for male patients due to its capability to induce treatment for hypogonadotrophic hypogonadism. Some individuals suffering from idiopathic dysspermias have shown positive responses to this medication. It is also used to address delayed puberty associated with inadequate function of the gonadotrophic pituitary glands and cryptorchidism (excluding cases caused by anatomical obstructions).
ZYHMG HCG is a well-known medication aiding both male and female patients in addressing infertility issues. Furthermore, it may have other applications in treating or preventing various medical conditions not detailed here.
Female patients considering ZYHCG treatment should be aware that those undergoing medically assisted reproduction, particularly in vitro fertilization, often experience tubal abnormalities and may encounter a higher incidence of ectopic pregnancies post-treatment. Therefore, early ultrasound verification to determine the location of the pregnancy (whether it’s intrauterine) is essential. Pregnancies that follow this treatment also face an increased risk of multiples. Female patients with thrombosis, severe obesity, or thrombophilia should avoid this medication due to a higher risk of arterial or venous thromboembolic events during or following HCG treatment. It's common for female patients treated with this medication to experience a higher likelihood of pregnancy loss.
In the case of male patients: Extended use of ZYHCG 10000 iu has been known to lead to enhanced androgen production. Consequently, patients with overt or latent cardiac failure, hypertension, renal dysfunction, migraine, or epilepsy may either be restricted from using this medication or may require a lower dosage of ZYHCG. Care should be exercised when administering this medication to prepubertal adolescents to minimize the risk of early sexual maturation or premature epiphyseal closure. The skeletal development of such patients should be monitored closely and regularly.
Both male and female patients with the following medical conditions should not begin treatment with ZYHCG: hypersensitivity to this medication or any of its components, as well as known or suspected androgen-dependent tumors, such as male breast cancer or prostate cancer.
Consult your doctor regarding the proper usage of this medication. It is crucial to adhere to any instructions provided by your physician. You may also refer to the medication's label for additional guidance. If you have further questions, consult your doctor, pharmacist, or nurse. ZYHCG should be refrigerated at a temperature between 2°-8°C. Keep this medication out of direct sunlight and away from children and pets to prevent accidental poisoning.
For female patients, the recommended dosage is one injection of 5,000-10,000 I.U. For male patients, the suggested dosage is an injection of 1,000-2,000 I.U. two to three times a week. It’s advisable that each ZYHCG dose is administered by a qualified healthcare professional.
This medication has a low acute toxicity profile, and the symptoms of an overdose in humans are not well known.
Extended treatment with this medication may cause various reactions at the injection site, such as pain, bruising, redness, itching, and swelling. Some patients receiving ZYHCG 10000 iu have reported allergic reactions manifesting as rash, pain, or swelling at the injection site. Rare side effects of ZYHCG may include fever or rash.
Female patients undergoing treatment with this product have reported unpleasant ovarian hyperstimulation syndrome. Male patients treated with ZYHCG might occasionally experience sodium and water retention, especially after higher doses, likely due to excess androgen production. In some cases, treatment with ZYHCG may result in gynaecomastia.